ClinicalTrials.gg
CompletedNCT01375244Updated Jun 17, 2011

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

A Phase 1 interventional study of Lisinopril and Zestril in Healthy, sponsored by Par Pharmaceutical, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-17.

Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Fasting by Par Health — none open to participants now, none under way, none of them phase 3. Fasting · Par Health.

Enrollment
8th of 19
36 · median 32
Started
1999
with 1 other
Phase 1
18 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Fasting by Par Health, this one is the 8th largest by enrollment, is one of 2 that started in 1999, is one of 18 in phase 1, and was the 1st registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

None of the 19 studies in Fasting by Par Health is open now. The open studies under Fasting, anywhere →

Where they have run

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Fasting by Par Health as a file.
02

Study summary

The purpose of this study is to compare the bioavailability of Par Lisinopril 10 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R).

Read the detailed description

To compare the bioavailability of Par and IPR (Zestril(R)), Lisinopril 10 mg Tablets under fasting conditions.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • bioequivalence
  • lisinopril
  • fasting
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, healthy, 18-50 years of age,
  • No more than plus or minus 15% from ideal weight for subject's height as defined by Metropolitan Life Insurance Company Statistical Bulletin 1983,
  • Without a history of asthma, angioedema, hypertension, psychiatric illness, organ-system (cardiovascular, neurological, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal,) disorders, ongoing infectious diseases, alcohol or drug abuse as determined by a medical history and/or physical examination within 30 days prior to the start of the study. Deviations may be acceptable if deemed not by the investigator.
  • Blood chemistry (including alkaline phosphatase, glucose, ALt, , LDH, BUN, GGT, creatinine, , electrolytes), hematology (including , hematocrit, red blood cell count, white blood cell count, differential, count), and urinalysis values within clinically acceptable limits upon evaluation by the investigator. The above tests will be performed within 30 days prior to the start of the study.
  • No prescription drugs within 14 days, or OTC preparations (with the exception of acetaminophen, vitamins, medicated lozenges, dietary supplements and topical medications) within 7 days of the first drug administration, each period. Deviations may be acceptable if evaluated by the investigator and determined not to be clinically significant.
  • No alcohol consumption for at least 48 hours prior to drug administration until after the last blood collection, each period.
  • No known allergy to lisinopril or other ACE (angiotensin converting enzyme) inhibitors, such as captopril and enalapril, or to atropine.
  • Acceptable : sinus rhythm with no evidence of AV block or ischemic changes.
  • At screening and check-in for each period, subjects must have blood pressure and pulse rate within the following ranges: Systolic blood pressure (110-150 mmHg); Diastolic blood pressure (70-95 mmHg); Pulse (50-105 bpm). Minor deviations (1-3 mmHg) at check-in may be acceptable at the discretion of the physician investigator. For all except the first period check-in, if a subject's vital signs measurements fall outside the range specified above, the subject may, at the discretion of the physician investigator, be allowed to remain enrolled until 0-hour measurements are made. If the 0-hour protocol vital signs requirements are met, the investigator may allow dosing and the subject's continuation in the study. If 0-hour vital signs requirements are not met, the subject will not be dosed and must be withdrawn from the study. The blood pressure and pulse will be measured after the subject has been seated at least three minutes. Subjects with blood pressure and pulse measurements outside the ranges will have their vital signs measurements repeated according to Standard Operating Procedure.
  • No caffeine for at least 48 hours prior to dosing until after the last blood collection, each period.
  • Negative 1, surface antigen and urine screen for drugs of abuse within 30 days prior to the start of the study.

Exclusion criteria

Exclusion Criteria:

  • All Females, and males younger than 18 years of age or older than 50 years of age are not eligible to participate in this study.
  • A weight that is more than plus or minus 15% from ideal weight for subject's height as defined by Metropolitan Life Insurance Company Statistical Bulletin 1983.
  • A medical history of asthma, angioedema hypertension, psychiatric illness, organ-system (cardiovascular, neurological, hepatic, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal) disorders, ongoing infectious diseases, alcohol or drug abuse within 30 days prior to start of the study.
  • Blood chemistry (including alkaline phosphatase, glucose, ALt, , LDH, BUN, GGT, creatinine, , electrolytes), hematology (including , hematocrit, red blood cell count, white blood cell count, differential, count), and urinalysis values not within clinically acceptable limits upon evaluation by the investigator. The above tests will be performed within 30 days prior to the start of the study.
  • Evidence of usage of prescription drugs within 14 days, or OTC preparations (with the exception of acetaminophen, vitamins, medicated lozenges, dietary supplements and topical medications) within 7 days of the first drug administration, each period.
  • Alcohol consumption within 48 hours prior to drug administration until.
  • Known allergy to lisinopril or other ACE (angiotensin converting enzyme) inhibitors, such as captopril and enalapril, or to atropine.
  • Unacceptable : sinus rhythm with evidence of AV block or ischemic changes.
  • Blood pressure and pulse rate outside of the following ranges: Systolic blood pressure (110-150 mmHg); Diastolic blood pressure (70-95 mmHg); Pulse (50-105 bpm).
  • Evidence of caffeine use within the last 48 hours, prior to dosing, or through the study up to and after the last blood collection, each period.
  • A positive 1, surface antigen and urine screen for drugs of abuse within 30 days prior to the start of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    A

    Subjects received the Par formulated product.

    Drug: Lisinopril

  • Active comparator
    B

    Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.

    Drug: Zestril

Interventions

  • Tablets, 10 mg, single dose

    Also known as: Zestril

  • Tablets, 10 mg, single dose

    Also known as: lisinopril

06

What researchers measure

Primary outcomes

  1. Rate and extent of absorption

    Time frame: 24 hours

07

Study locations

1 site
  • PharmaKinetics Laboratories, Inc.
    Baltimore, Maryland 21201, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1999, a primary completion of Oct 1999 and a completion of Oct 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Jun 17, 2011
Start
Jun 1999
Primary completionActual
Oct 1999
CompletionActual
Oct 1999
Last update
Jun 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01375244
Collaborators
PharmaKinetics Laboratories Inc.
First posted
Jun 17, 2011
Start date
Jun 1999
Primary completion
Oct 1999
Completion
Oct 1999
Last update
Jun 17, 2011

Study contacts

Clifford L Ferguson, MD
principal investigator · PharmaKinetics Laboratories Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisinopril

Start the discussion